Viridian Therapeutics, INC.\De (VRDN) SEC Filings — 2025

Filings

• Viridian Therapeutics Files 8-K on Financials — 8-K · Nov 5, 2025
• Viridian Narrows Q3 Loss to $34.6M on Soaring License Revenue — 10-Q · Nov 5, 2025
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Oct 23, 2025
• Viridian Therapeutics Files 8-K on Financials — 8-K · Oct 21, 2025
• Viridian Therapeutics Enters Material Definitive Agreement — 8-K · Oct 20, 2025
• Viridian Therapeutics Files 8-K on Financials — 8-K · Aug 6, 2025
• Viridian's Q2 Net Loss Widens to $60.2M Amid R&D Surge — 10-Q · Aug 6, 2025
• Viridian Therapeutics Files 8-K: Material Agreement Announced — 8-K · Jul 30, 2025
• Viridian Therapeutics Files 8-K on Officer/Director Changes — 8-K · Jun 24, 2025
• Viridian Therapeutics Files 8-K — 8-K · May 20, 2025
• Viridian Therapeutics Files 8-K on Financials — 8-K · May 6, 2025
• Viridian Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025
• Viridian Therapeutics Files DEF 14A for FY2024 — DEF 14A · Apr 25, 2025
• Viridian Therapeutics Board Changes & Filings — 8-K · Apr 7, 2025
• Viridian Therapeutics Announces Board and Executive Changes — 8-K · Mar 10, 2025
• Viridian Therapeutics Terminates Material Definitive Agreement — 8-K · Mar 4, 2025
• Viridian Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025
• Viridian Therapeutics Files 8-K on Financials — 8-K · Feb 27, 2025
• Viridian Therapeutics Announces Board and Officer Changes — 8-K · Jan 10, 2025